{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:18:06Z","timestamp":1789492686258,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"BIRAX","award":["69BX18TPAL"],"award-info":[{"award-number":["69BX18TPAL"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in neovascular age-related macular degeneration (nAMD) using automated volumetric retinal fluid analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study included 186 eyes with nAMD showing inadequate response after \u22653 bevacizumab injections. Patients were switched to a second-line anti-VEGF agent and categorized as early (3\u20135 injections) or late (\u22656 injections) switchers. Optical coherence tomography (OCT) scans were analyzed using the Notal-OCT Analyzer (NOA), an AI-based algorithm for retinal fluid quantification. Parameters included total retinal fluid (TRF), intraretinal fluid (IRF) volume, subretinal fluid (SRF) volume, pigment epithelial detachment (PED) volume, central subfield thickness (CST), and visual acuity (VA), assessed at baseline, after bevacizumab, and after three injections of the new agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Early switchers showed an increase in TRF from 105 nL to 158 nL after bevacizumab, then a reduction to 20 nL postswitch (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001); PED volume decreased postswitch (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.010). Late switchers showed fluid reductions both after bevacizumab and postswitch (TRF:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; PED:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007). CST significantly improved only in early switchers (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), while VA changes were not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Automated fluid analysis reliably quantifies treatment response in nAMD. Early switchers showed worsening after bevacizumab, while late switchers had partial responses. These findings highlight the potential of automated analysis to support more individualized, data-driven treatment strategies. Prospective studies are required to confirm impact on patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004756","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T19:00:45Z","timestamp":1767639645000},"page":"897-904","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["ANTI-VEGF THERAPY SWITCHING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"46","author":[{"given":"Omer","family":"Dor","sequence":"first","affiliation":[{"name":"Ophthalmology DivisionTel Aviv Sourasky Medical Center, Tel Aviv, Israel;"},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel;"},{"name":"Edmond J Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Cohen","sequence":"additional","affiliation":[{"name":"Ophthalmology DivisionTel Aviv Sourasky Medical Center, Tel Aviv, Israel;"},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marganit","family":"Shahar-Gonen","sequence":"additional","affiliation":[{"name":"Ophthalmology DivisionTel Aviv Sourasky Medical Center, Tel Aviv, Israel;"},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[{"name":"Ophthalmology DivisionTel Aviv Sourasky Medical Center, Tel Aviv, Israel;"},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen's University Belfast, Belfast, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wright","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen's University Belfast, Belfast, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reut","family":"Shor","sequence":"additional","affiliation":[{"name":"Ophthalmology DivisionTel Aviv Sourasky Medical Center, Tel Aviv, Israel;"},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Havilio","sequence":"additional","affiliation":[{"name":"Notal Vision, LtdTel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gidi","family":"Benyamini","sequence":"additional","affiliation":[{"name":"Notal Vision, LtdTel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wen","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen's University Belfast, Belfast, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Shomron","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel;"},{"name":"Edmond J Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-444X","authenticated-orcid":false,"given":"Dinah","family":"Zur","sequence":"additional","affiliation":[{"name":"Ophthalmology DivisionTel Aviv Sourasky Medical Center, Tel Aviv, Israel;"},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/eye.2017.7","article-title":"Aflibercept as a second line therapy for neovascular age related macular degeneration in Israel (ASLI) study","volume":"31","author":"Tiosano","year":"2017","journal-title":"Eye"},{"issue":"Suppl 1","key":"R4-20260915","doi-asserted-by":"crossref","first-page":"i22","DOI":"10.1136\/bjophthalmol-2013-304798","article-title":"A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis","volume":"98","author":"Singh","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ajo.2014.11.022","article-title":"One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration","volume":"159","author":"Arcinue","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2013.02.017","article-title":"Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab","volume":"156","author":"Bakall","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","article-title":"Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration","volume":"121","author":"Chang","year":"2014","journal-title":"Ophthalmology"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00417-014-2589-3","article-title":"Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD","volume":"252","author":"Fassnacht-Riederle","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/eye.2014.101","article-title":"Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results","volume":"28","author":"Grewal","year":"2014","journal-title":"Eye"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2013.02.009","article-title":"Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors","volume":"156","author":"Ho","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/bjophthalmol-2013-304829","article-title":"Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration","volume":"98","author":"Messenger","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bjophthalmol-2013-304736","article-title":"Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)","volume":"98","author":"Wykoff","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/bjo.2011.204685","article-title":"Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation","volume":"96","author":"Gasperini","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s12325-019-00971-0","article-title":"How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview","volume":"36","author":"Empeslidis","year":"2019","journal-title":"Adv Ther"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5301\/ejo.5000757","article-title":"Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results","volume":"26","author":"Aghdam","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1111\/aos.14046","article-title":"Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration","volume":"97","author":"Spooner","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","article-title":"Automated identification of lesion activity in neovascular age-related macular degeneration","volume":"123","author":"Chakravarthy","year":"2016","journal-title":"Ophthalmology"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","article-title":"Fully automated detection and quantification of macular fluid in OCT using deep learning","volume":"125","author":"Schlegl","year":"2018","journal-title":"Ophthalmology"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2020.09.025","article-title":"Quantitative analysis of OCT for neovascular age-related macular degeneration using deep learning","volume":"128","author":"Moraes","year":"2021","journal-title":"Ophthalmology"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/IAE.0000000000003023","article-title":"Analysis of fluid volume and its impact on visual acuity in the fluid study as quantified with deep learning","volume":"41","author":"Reiter","year":"2021","journal-title":"Retina (Philadelphia, PA)"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"100972","DOI":"10.1016\/j.preteyeres.2021.100972","article-title":"AI-based monitoring of retinal fluid in disease activity and under therapy","volume":"86","author":"Schmidt-Erfurth","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jamaophthalmol.2020.2769","article-title":"Model-to-Data approach for deep learning in optical coherence tomography intraretinal fluid segmentation","volume":"138","author":"Mehta","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12886-018-0824-0","article-title":"Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept","volume":"18","author":"Tyagi","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","article-title":"Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration","volume":"121","author":"Simader","year":"2014","journal-title":"Ophthalmology"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","article-title":"Impact of Intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial","volume":"6","author":"Riedl","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10792-016-0294-4","article-title":"Intravitreal aflibercept in treatment-resistant pigment epithelial detachment","volume":"37","author":"Kocak","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:00:15Z","timestamp":1789491615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004756"}},"subtitle":["Insights from Automated Volumetric Retinal Fluid Analysis"],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004756","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}